After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

I felt fine, but my Whoop data told a different story. Paying attention led to early detection and a successful treatment.

Abbott (NYSE: ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with ...

Shorter, nanosecond pulses for treating atrial fibrillation differentiate the company’s approach from existing pulsed field ...

The FDA approved Abbott's Volt PFA System for atrial fibrillation, supported by VOLT-AF trial data showing strong safety and ...

The latest update is out from Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:IMR) ). Imricor Medical Systems has ...

Abbott received approval from the Food and Drug Administration for its Volt Pulsed Field Ablation System to treat atrial fibrillation. The medical technology company said Monday that it would soon ...

Two years after the U.S. FDA approved the first pulsed field ablation system, Abbott Laboratories finally got the regulatory nod for its Volt PFA system. Abbott follows Medtronic plc, Boston ...

An ongoing trial at the Medical University of South Carolina is looking for a breakthrough for patients dealing with heart ...

"Holiday heart syndrome" is an umbrella term for several cardiac complications that occur during the winter holiday season.

Nurse scientist Linda Park, PhD, uses NIH funding to study cardiac rehab and digital tools—like pedometers and apps—to ...

In 2023, UCSF became the first to boast an all-female heart transplant team led by Amy Fiedler, MD, who featured in an iconic ...